oral non-peptide GLP-1R GPCR partial agonist

in Ph. I for Type 2 diabetes, HV study complete

from cell-based screen and opt.

PNAS, Nov. 11, 2020

Chugai, Shizuoka, JP / Eli Lilly, Indianapolis, IN

LY3502970

Chugai/Lilly clinical oral non-peptide GLP-1R GPCR partial agonist


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: